John Shannon compensation by year
Xeris Biopharma Summary Compensation Table · all 6 fiscal years held| Component | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Salary | $473,658 | $527,500 | $549,433 | $571,411 | $629,193 | $742,334 |
| Bonus | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $414,050 | $762,000 | $702,500 | $930,000 | $2,452,500 | $2,848,000 |
| Option awards | $246,300 | $0 | $0 | $0 | $309,037 | $838,615 |
| Non-equity incentive | $300,000 | $396,175 | $275,600 | $343,949 | $433,475 | $607,971 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $2,420 | $42,965 | $2,685 | $2,793 | $2,904 | $5,664 |
| Total | $1,436,428 | $1,728,640 | $1,530,218 | $1,848,153 | $3,827,109 | $5,042,584 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Xeris Biopharma Holdings, Inc. DEF 14A filed April 23, 2026, accession 0001867096-26-000021, and prior-year filings.
How this page was built: the Xeris Biopharma Holdings, Inc. filed document, accession 0001867096-26-000021. Every figure is read from that document and cited to the page and table it appears in. Filed April 23, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 800,000 | $6,280,000 | — |
| RSU | 500,000 | $3,925,000 | — |
| RSU | 250,000 | $1,962,500 | — |
| RSU | 166,666 | $1,308,328 | — |
| Option | 300,000 | — | $2.43 |
| Option | 600,000 | — | $3.56 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Xeris Biopharma Holdings, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
1 Form 4 line since the FY2025 proxy (filed April 23, 2026)current to 2026-11-07 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-08-01 | Tax withholding | — | 36,645 | $8.08 | 2,898,933 |
The 1 most recent of 1 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments Xeris Biopharma discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Resignation for good reason, no change in control | $1,122,000 | $0 | $57,317 | $1,908,617 |
| Change in control and involuntary termination | $2,468,400 | $17,675,828 | $57,317 | $20,205,457 |
Per the Potential Payments Upon Termination or Change in Control table in Xeris Biopharma Holdings, Inc.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
Xeris Biopharma’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| John Shannon · this page | Chief Executive Officer | $5,042,584 |
| Kevin McCulloch | President and Chief Operating Officer | $2,270,973 |
| Anh Nguyen | Chief Medical Officer | $2,000,648 |
| Beth Hecht | Chief Legal Officer and Corporate Secretary | $1,895,274 |
| Steven Pieper | Chief Financial Officer | $1,874,090 |
Board service
Xeris Biopharma board · FY2024–FY2025How this board is paid
Company policy: Xeris Biopharma pays directors a $50,000 cash retainer and $300,000 in RSUs. As stated in Xeris Biopharma's FY2025 proxy.
The full Xeris Biopharma compensation record
free company briefThis page is one person within Xeris Biopharma's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Xeris Biopharma proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Xeris Biopharma's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Xeris Biopharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.